FDA Inspection 961508 — Sato Pharmaceutical Co., Ltd.

Sato Pharmaceutical Co., Ltd. — FEI 3004055563

The FDA completed an inspection of Sato Pharmaceutical Co., Ltd. on February 12, 2016 in Hachioji. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 6 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
February 12, 2016
Fiscal Year
2016
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Hachioji (Japan)

Citations

IDCFRDescription
143321 CFR 211.42(c)(10)(iii)Air Supply
143421 CFR 211.42(c)(10)(iv)Environmental Monitoring System
145221 CFR 211.113(b)Validation lacking for sterile drug products
179021 CFR 211.80(b)Handling and Storage to Prevent Contamination
203321 CFR 211.194(c)Testing and standardization of standards et. al.
239921 CFR 211.194(a)(2)Laboratory Test Method Verification